Alembic Pharmaceuticals Limited — Others, 06-05-2025: Change in Auditors

Alembic Pharmaceuticals has announced a board meeting on which it approved the audited financial results for the quarter and financial year ended March 31, 2025, and proposed a dividend of Rs. 11 per share (550%) pending shareholder approval. The company appointed M/s. KKC & Associates LLP as new statutory auditors for five years, replacing the previous auditor, and M/s. Samdani Shah & Kabra as Secretarial Auditors for five years, subject to approval. Revenue rose to Rs. 6,672 Cr with a profit before tax of Rs. 707 Cr. Net profit stood at Rs. 583 Cr. The company received an insurance claim of Rs. 83.6 Cr related to past flood damages. Resumption of formulation manufacturing in Sikkim supports recovery, and low debt-equity ratio at 0.23 signals financial strength.